InicioATBPF • OTCMKTS
add
Antibe Therapeutics Ord Shs
Cierre anterior
0,22 $
Intervalo anual
0,11 $ - 0,89 $
Volumen medio
27,54 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (CAD) | dic 2023info | Cambio interanual |
|---|---|---|
Ingresos | — | — |
Gastos operativos | 4,60 M | -1,42 % |
Ingresos netos | -4,21 M | 2,39 % |
Margen de beneficio neto | — | — |
Beneficios por acción | -0,08 | -32,96 % |
EBITDA | — | — |
Tipo impositivo efectivo | — | — |
Balance general
Activos totales
Responsabilidades totales
| (CAD) | dic 2023info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 24,91 M | -41,20 % |
Activos totales | 56,36 M | -23,56 % |
Responsabilidades totales | 30,42 M | -0,13 % |
Patrimonio total | 25,94 M | — |
Acciones en circulación | 52,67 M | — |
Precio-valor contable | 0,44 | — |
Rentabilidad económica | -19,71 % | — |
Retorno sobre capital | -41,30 % | — |
Flujo de caja
Variación neta del flujo de caja
| (CAD) | dic 2023info | Cambio interanual |
|---|---|---|
Ingresos netos | -4,21 M | 2,39 % |
Efectivo de operaciones | -3,84 M | -6,66 % |
Efectivo de inversión | 11,04 M | 1.975,38 % |
Efectivo de financiación | — | — |
Variación neta del flujo de caja | 7,20 M | 334,09 % |
Flujo de caja libre | -2,47 M | -2.419,13 % |
Información sobre la empresa
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
Fundación
2009
Sitio web
Empleados
11
